top of page

Rusfertide Meets Primary Endpoint in Clinical Trial for PV patients

Protagonist Therapeutics, Inc., announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE, a study evaluating rusfertide, a subcutaneous injectable hepcidin mimetic, in patients with polycythemia vera (PV).

Want to read more?

Subscribe to www.gmpnsf.org to keep reading this exclusive post.

Subscribe Now
29 views0 comments
bottom of page